Table 4.
Baseline clinical characteristics, nirsERT results and clinical outcomes of 22 patients undergoing IVF
| Normal WOI |
Displaced WOI |
P-value | Detection failed | Total | |
|---|---|---|---|---|---|
| Date of transfer | LH + 7/P + 5 | LH + 7/P + 5 | LH + 7/P + 5 | / | |
| Predicted result | Receptivity | Pre-receptivity | / | / | |
| No. of patients | 18 | 3 | 1 | 22 | |
| Age, Mean ± SD, y | 30.4 ± 3.87 | 28.67 ± 3.51 | 0.466 | 33 | / |
| BMI, Mean ± SD, kg/m2 | 20.95 ± 2.49 | 22.53 ± 0.76 | 0.297 | 21.6 | / |
| Infertility duration, Median (IQR), y | 2(1–5) | 2a | 0.387 | 5 | / |
| AMH, Median (IQR), ng/ml | 2.90(2.36–5.29) | 6.32a | 0.430 | 3.10 | / |
| FSH, Mean ± SD, mIU/ml | 5.74 ± 0.88 | 5.70 ± 1.33 | 0.952 | 4.67 | / |
| Endometrial thickness, Mean ± SD, mm | 11.21 ± 2.03 | 9.33 ± 2.14 | 0.158 | 11.80 | / |
| P levels on the day of progesterone administration/LH peak, Median (IQR), ng/ml | 0.90 (0.06–0.20) | 0.57a | 0.164 | 0.61 | / |
| IVF indication | |||||
| Tubal factor (n/%) | 14 (77.8%) | 1 (33.3%) | 0.242 | 1 | / |
| PCOS (n/%) | 3 (16.7%) | 2 (66.7%) | / | / | |
| Ovulation disorder (n/%) | 2(11.1%) | 1 (33.3%) | / | / | |
| Male factor (n/%) | 1(5.6%) | 0 | / | / | |
| Diminished ovarian reserve (n/%) | 1(5.6%) | 0 | / | / | |
| Cycle protocol | |||||
| Natural cycle (n/%) | 7(38.9%) | 1(33.3%) | 0.101 | / | 8 |
| HRT cycle (n/%) | 11(61.1%) | 2(66.7%) | 1 | 14 | |
| No. of intrauterine pregnancy | 14 | 0 | 0 | 14 | |
| Intrauterine pregnancy rate | 77.8%(14/18) | 0 | 0.026 | 0 | 63.6%(14/22) |
| Live birth rate | 72.2%(13/18) | 0 | 0.042 | 0 | 59.1%(13/22) |
Abbreviations: nirsERT non-invasive RNA-seq-based endometrial receptivity test, BMI body mass index, AMH antimullerian hormone, FSH follicle-stimulating hormone, PCOS polycystic ovarian syndrome
aOnly the Median is listed because there are only three samples